Initiator Pharma A/S
16 Jun - 30 Jun 2022Rights issue
Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of three clinical programs – the clinical programs IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drugprogram IPTN2021 for Trigeminal Neuralgia, a severe neuropathic pain condition.
Initiator started off as a spin-out company from Saniona AB together with Dr. Claus Olesen, Dr. Dan Peters, Professor Ulf Simonsen and Dr. Mikael Thomsen, with the business idea of further developing a family of drug candidates based on so-called MRI technology (Monoamine Reuptake Inhibitor). The technology aims to inhibit the reuptake of monoamines in the body’s nerves and thereby increase dopamine levels in various parts of the brain and body. Dopamine is an important neurological signaling substance, and by increasing the dopamine level, a number of different diseases can be treated. All founders of Initiator have long and solid experience of preclinical and clinical drug development and are also world-leading researchers in erectile dysfunction and MRI technology, which forms the basis for the company’s drug candidates.
The offer in summary
Record date: 10 June 2022
Subscription period: 16 June - 30 June 2022
Subscription rights: Shareholders by the record date of 10 June 2022 will obtain one (1) subscription right per existing share. In order to subscribe for two (2) new shares, seventeen (17) subscription rights are exercised.
Subscription price: SEK 7.50
The offer: 5 463 426 shares
Trading with rights: 16 June - 27 June 2022
Market place: Nasdaq First North
Financial advicor: Sedermera Corporate Finance AB